Rituximab bioavailability in primary membranous nephropathy

Nephrol Dial Transplant. 2019 Aug 1;34(8):1423-1425. doi: 10.1093/ndt/gfz041.

Authors

Affiliations

¹ Service de Néphrologie-Dialyse-Transplantation, Hôpital Pasteur, CHU de Nice, Université de Nice-Sophia Antipolis, Nice, France.
² Laboratoire d'Immunologie, Hôpital l'Archet, CHU de Nice, Université de Nice-Sophia Antipolis, Nice, France.
³ Division of Renal Diseases and Hypertension, University of Minnesota, Minneapolis, MN, USA.
⁴ CNRS and Université de Nice-Sophia Antipolis, Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275, Valbonne Sophia-Antipolis, France.

PMID: 30929012
DOI: 10.1093/ndt/gfz041

No abstract available

MeSH terms

Angiotensin Receptor Antagonists / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
B-Lymphocytes / immunology
Biological Availability*
Biomarkers / urine
Case-Control Studies
Female
Glomerulonephritis, Membranous / drug therapy*
Glomerulonephritis, Membranous / urine*
Humans
Immunologic Factors / therapeutic use
Immunologic Factors / urine
Male
Myasthenia Gravis / drug therapy
Myasthenia Gravis / immunology
Myasthenia Gravis / urine
Nephrosis / urine
Proteinuria / complications
ROC Curve
Receptors, Phospholipase A2 / immunology
Rituximab / therapeutic use*
Rituximab / urine
Thrombospondins / immunology

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Biomarkers
Immunologic Factors
PLA2R1 protein, human
Receptors, Phospholipase A2
THSD7A protein, human
Thrombospondins
Rituximab